Antibody-drug conjugates (ADCs) are a new type of targeted therapy which are very promising in cancer treatment that significantly increase target specificity as well as reduce toxcity. ADCs are cell specific monoclonal antibodies that are conjugated with highly potent cyotoxics though a specific linker that help to deliver and release the drug inside the tumor cell.
A recent study published in Molecular Cancer Therapeutics focused on evaluating the therapeutic potential of a new Antibody-drug conjugate (ADC), SYD985. SYD985 is a HER2-targeting antibody–drug conjugate (ADC) based on trastuzumab and vc-seco-DUBA. The purpose of this research was to evaluate the therapeutic potential of
this new ADC for treatment of
patients with breast cancer. This evauation was accomplished by comparing its preclinical antitumor
activity directly to that of T-DM1 in a series of high and low
HER2-expressing breast cancer PDX models.
The promise of ADCs as a new class of drugs in
oncology is evident in the high number of ADCs that are currently in clinical development and even more that are in preclinical
programs and studies. Read More